Composition for use in increasing engraftment efficacy of haematopoetic stem cells after transplantation
AssigneeSciPharm SaRL
InventorsMichael Freissmuth, Eva-Maria Zebedin-Brandl, Zahra Kazemi
Life of this patent
Estimating the term…
Abstract
The present invention provides the new use of composition comprising at least one inhibitor of dipeptidyl peptidase IV (DPP-IV) for increasing migration and homing of haematopoetic progenitor cells in stem cell transplanted recipients, wherein said haematopoetic stem and/or progenitor cells had been treated in vitro with an engraftment enhancing compound, specifically with a prostacyclin analogue and a cAMP enhancer before transplantation.
Claims17
A method of treating a subject who has received a haematopoetic stem cell transplant comprising haematopoetic stem cells and/or progenitor cells, comprising the step of administering an inhibitor of dipeptidyl peptidase IV (DPP-IV) to the subject, wherein said haematopoetic stem cells and/or progenitor cells are treated in vitro before transplantation with a prostacyclin analogue to enhance engraftment.
A method for enhancing the engraftment capabilities of haematopoetic cells, comprising the sequential steps of:
- a) providing a sample of haematopoetic stem cells or progenitor cells,
- b) administering an effective amount of a prostacyclin analogue and a cAMP enhancer to said cells,
- c) incubating said mixture for a period of time sufficient to stimulate G alphas-signaling in said cells,
- d) isolating said cells,
- e) transplanting said cells into an individual in need thereof, and
- f) administering to said individual an effective amount of a DPP-IV inhibitor.
Dependencies are inferred from the claim text.